MannKind | MNKD - Ebit

Stock Price
3.09
Daily Change
-0.13 -4.04%
Monthly
12.36%
Yearly
-29.29%
Q2 Forecast
3.03

MannKind reported $-76.99M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Adma Biologics USD 62.75M 13.56M Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Insmed USD -200.28M 49.43M Mar/2026
Karyopharm Therapeutics USD -17.84M 8.44M Dec/2025
MacroGenics USD -12.1M 32.26M Dec/2025
MannKind USD -76.99M 7.75M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Novavax USD 20.94M 100.32M Dec/2025
Novo Nordisk DKK 5.18B 37.04B Jun/2025
Pfizer USD 4.99B 340M Mar/2026
Sanofi EUR 1.94B 239M Mar/2026
Xencor USD -77.86M 24.23M Mar/2026